Rare Disease Spotlight-oncology therapies dominate the orphan drug landscape
The second edition of the Rare Disease Spotlight series investigates the trends in orphan drug designations across therapy areas over…
By
Gastrointestinal
Latest in
Gastrointestinal
US FDA grants approval for Azurity’s Konvomep to treat gastric ulcer
The company plans to make Konvomep available commercially in the US by the first quarter of next year.
GentiBio and BMS partner to develop inflammatory bowel disease therapies
BMS will make development and commercial milestone payments of up to $1.9bn to GentiBio.
EC grants approval for AbbVie’s Rinvoq to treat ulcerative colitis in adults
The latest approval is based on findings from three randomised, multicentre, Phase III trials of Rinvoq.
Takeda announces 11.6% reported revenue growth in FY2021
For the fiscal year, the operating cash flow witnessed a 11.1% rise to $8.63bn (JPY1,123.1bn).
Will Dupixent change the treatment paradigm for EoE?
Key opinion leaders expect Dupixent to target patients who do not respond to current oeosinophilic oesophagitis (EoE) therapies.
By
Kallyope raises $236m to develop gut-brain axis treatment programmes
The proceeds will be used to advance the development of its compounds currently in clinical trials.
Pfizer signs agreement to acquire Arena Pharmaceuticals for $6.7bn
Arena’s portfolio includes several candidates in gastroenterology, dermatology and cardiology.